GSK to invest $120m to expand manufacturing facility in US

SourcePharmaceutical Technology
Date Published09/26/2019
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name GlaxoSmithKline
Parent companyGlaxoSmithKline
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Capital investment ($):120
Country(ies) from which reshored:United Kingdom
City reshored to:King of Prussia
State(s) reshored to:PA
If relevant, work nearshored to:-
Product(s) reshoredspecialty medicines
What domestic positive factors made reshoring more attractive?Automation/technology, Customer responsiveness improvement, Customization/Flexibility, Infrastructure, Image/brand, Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training, Other, expansion
Find Reshoring Articles